Suiseng Diff/A RSS Authorised This medicine is authorised for use in the European Union clostridioides difficile / clostridium perfringens vaccine, inactivated Medicine Veterinary Authorised
Page contentsPage contents Overview Product information Product details Authorisation details Assessment history News on Suiseng Diff/A Application under evaluation CVMP opinion European Commission decision OverviewUp-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website Suiseng Diff/A : EPAR - Medicine Overview English (EN) (81.94 KB - PDF)First published: 24/01/2022 Last updated: 14/10/2025 View Other languages (25) български (BG) (93.36 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View español (ES) (81.97 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View čeština (CS) (93.99 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View dansk (DA) (83.34 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View Deutsch (DE) (82.76 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View eesti keel (ET) (82.18 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View ελληνικά (EL) (93.76 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View français (FR) (82.44 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View hrvatski (HR) (92.27 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View íslenska (IS) (83.29 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View Gaeilge (GA) (83.57 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View italiano (IT) (82.29 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View latviešu valoda (LV) (94.29 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View lietuvių kalba (LT) (94.03 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View magyar (HU) (94.15 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View Malti (MT) (95.95 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View Nederlands (NL) (82.05 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View norsk (NO) (82 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View polski (PL) (95.62 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View português (PT) (83.01 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View română (RO) (94.17 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View slovenčina (SK) (94.08 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View slovenščina (SL) (82.27 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View Suomi (FI) (81.54 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View svenska (SV) (82.05 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View Product information Suiseng Diff/A : EPAR - Product Information English (EN) (81.49 KB - PDF)First published: 24/01/2022 Last updated: 14/10/2025 View Other languages (25) български (BG) (91.78 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View español (ES) (81.51 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View čeština (CS) (92.48 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View dansk (DA) (82.05 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View Deutsch (DE) (81.72 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View eesti keel (ET) (81.22 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View ελληνικά (EL) (91.79 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View français (FR) (81.63 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View hrvatski (HR) (91.56 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View íslenska (IS) (81.52 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View Gaeilge (GA) (81.36 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View italiano (IT) (81.76 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View latviešu valoda (LV) (92.14 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View lietuvių kalba (LT) (92.19 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View magyar (HU) (92.76 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View Malti (MT) (93.86 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View Nederlands (NL) (81.15 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View norsk (NO) (81.52 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View polski (PL) (93.22 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View português (PT) (82.53 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View română (RO) (91.73 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View slovenčina (SK) (81.75 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View slovenščina (SL) (81.76 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View Suomi (FI) (81.11 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View svenska (SV) (81.47 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View Suiseng Diff/A : EPAR - All authorised presentations English (EN) (81.94 KB - PDF)First published: 24/01/2022 Last updated: 14/10/2025 View Other languages (25) български (BG) (93.36 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View español (ES) (81.97 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View čeština (CS) (93.99 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View dansk (DA) (83.34 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View Deutsch (DE) (82.76 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View eesti keel (ET) (82.18 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View ελληνικά (EL) (93.76 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View français (FR) (82.44 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View hrvatski (HR) (92.27 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View íslenska (IS) (83.29 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View Gaeilge (GA) (83.57 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View italiano (IT) (82.29 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View latviešu valoda (LV) (94.29 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View lietuvių kalba (LT) (94.03 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View magyar (HU) (94.15 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View Malti (MT) (95.95 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View Nederlands (NL) (82.05 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View norsk (NO) (82 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View polski (PL) (95.62 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View português (PT) (83.01 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View română (RO) (94.17 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View slovenčina (SK) (94.08 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View slovenščina (SL) (82.27 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View Suomi (FI) (81.54 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View svenska (SV) (82.05 KB - PDF) First published: 24/01/2022 Last updated: 14/10/2025 View Product details Name of medicine Suiseng Diff/A Active substance Clostridioides difficile toxoid AClostridioides difficile toxoid BClostridium perfringens, type A, alpha toxoid International non-proprietary name (INN) or common name clostridioides difficileclostridium perfringens vaccine, inactivated Pharmacotherapeutic groupImmunologicals for Suidae, inactivated bacterial vaccines for pigs, clostridium Authorisation details EMA product number EMEA/V/C/005596 Assessment history Expand section Collapse section Changes since initial authorisation of medicine CVMP post-authorisation summary of positive opinion for Suiseng Diff/AAdopted Reference Number: EMA/CVMP/436655/2023 English (EN) (138.46 KB - PDF)First published: 06/10/2023 View Initial marketing authorisation documents Suiseng Diff/A : EPAR - Public assessment reportAdopted English (EN) (81.49 KB - PDF)First published: 24/01/2022 Last updated: 14/10/2025 View CVMP summary of positive opinion for Suiseng Diff/AAdopted Reference Number: EMA/CVMP/522701/2021 English (EN) (128.15 KB - PDF)First published: 08/10/2021 View News on Suiseng Diff/A Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 12-13 March 202418/03/2024 Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 3-5 October 202306/10/2023 Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 5-7 October 202108/10/2021 This page was last updated on 14/10/2025 Share this page